Aurinia Pharmaceuticals I...

8.04
-0.15 (-1.83%)
At close: Apr 03, 2025, 3:59 PM
8.01
-0.44%
Pre-market: Apr 04, 2025, 04:31 AM EDT

Aurinia Pharmaceuticals Statistics

Share Statistics

Aurinia Pharmaceuticals has 137.34M shares outstanding. The number of shares has increased by -3.97% in one year.

Shares Outstanding 137.34M
Shares Change (YoY) -3.97%
Shares Change (QoQ) -4.08%
Owned by Institutions (%) 40.33%
Shares Floating 122.12M
Failed to Deliver (FTD) Shares 137.76K
FTD / Avg. Volume 9.55%

Short Selling Information

The latest short interest is 7.48M, so 5.22% of the outstanding shares have been sold short.

Short Interest 7.48M
Short % of Shares Out 5.22%
Short % of Float 5.81%
Short Ratio (days to cover) 5.5

Valuation Ratios

The PE ratio is 223.34 and the forward PE ratio is 14.33. Aurinia Pharmaceuticals's PEG ratio is -2.08.

PE Ratio 223.34
Forward PE 14.33
PS Ratio 5.46
Forward PS 2.7
PB Ratio 3.4
P/FCF Ratio 29.13
PEG Ratio -2.08
Financial Ratio History

Enterprise Valuation

Aurinia Pharmaceuticals has an Enterprise Value (EV) of 1.28B.

EV / Sales 5.45
EV / EBITDA 40.36
EV / EBIT 28.85
EV / FCF 29.03

Financial Position

The company has a current ratio of 4.57, with a Debt / Equity ratio of 0.21.

Current Ratio 4.57
Quick Ratio 4.17
Debt / Equity 0.21
Debt / EBITDA 2.5
Debt / FCF 1.8
Interest Coverage -0.97

Financial Efficiency

Return on Equity is 1.52% and Return on Invested Capital is -0.77%.

Return on Equity 1.52%
Return on Assets 1.04%
Return on Invested Capital -0.77%
Revenue Per Employee $1.81M
Profits Per Employee $44.25K
Employee Count 130
Asset Turnover 0.43
Inventory Turnover 0.72

Taxes

Income Tax 1.7M
Effective Tax Rate 22.77%

Stock Price Statistics

The stock price has increased by 57.96% in the last 52 weeks. The beta is 1.22, so Aurinia Pharmaceuticals's price volatility has been higher than the market average.

Beta 1.22
52-Week Price Change 57.96%
50-Day Moving Average 8.11
200-Day Moving Average 7.4
Relative Strength Index (RSI) 45.29
Average Volume (20 Days) 1.44M

Income Statement

In the last 12 months, Aurinia Pharmaceuticals had revenue of 235.13M and earned 5.75M in profits. Earnings per share was 0.04.

Revenue 235.13M
Gross Profit 206.88M
Operating Income -4.69M
Net Income 5.75M
EBITDA 31.73M
EBIT 12.28M
Earnings Per Share (EPS) 0.04
Full Income Statement

Balance Sheet

The company has 83.43M in cash and 79.37M in debt, giving a net cash position of 4.06M.

Cash & Cash Equivalents 83.43M
Total Debt 79.37M
Net Cash 4.06M
Retained Earnings -936.57M
Total Assets 550.64M
Working Capital 348.83M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 44.39M and capital expenditures -281K, giving a free cash flow of 44.11M.

Operating Cash Flow 44.39M
Capital Expenditures -281K
Free Cash Flow 44.11M
FCF Per Share 0.31
Full Cash Flow Statement

Margins

Gross margin is 87.99%, with operating and profit margins of -1.99% and 2.45%.

Gross Margin 87.99%
Operating Margin -1.99%
Pretax Margin 3.17%
Profit Margin 2.45%
EBITDA Margin 13.49%
EBIT Margin -1.99%
FCF Margin 18.76%

Dividends & Yields

AUPH does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield 0.45%
FCF Yield 3.43%
Dividend Details

Analyst Forecast

The average price target for AUPH is $11.5, which is 43% higher than the current price. The consensus rating is "Buy".

Price Target $11.5
Price Target Difference 43%
Analyst Consensus Buy
Analyst Count 2
Stock Forecasts

Stock Splits

The last stock split was on Oct 23, 2013. It was a backward split with a ratio of 1:50.

Last Split Date Oct 23, 2013
Split Type backward
Split Ratio 1:50

Scores

Altman Z-Score 2.69
Piotroski F-Score 7